Wednesday, August 28, 2013
Tuesday, August 27, 2013
NBCC deadline 2020
NBCC has a deadline 2020 project that seeks to end breast cancer by 2020. They are currently fund raising with 2:1 matching, so you triple your gift match with donation until 9/30/2013.
I'm reading up on their progress report:
I like the fact that NBCC put a deadline date for BC. This is unlike other charities that just splashes pink year after year till the founders live to a cushy retirement, and generations of women get marched through the adjuvant BC revenue generation therapy and get decimated by the MBC.
http://www.breastcancerdeadline2020.org/about-the-deadline/progress-reports/2012-progress-report.html
They fund a project called artemis that tries to end breast cancer by preventing metastatic breast cancer(MBC), it's another way of saying they are going to end breast cancer by researching adjuvant BC treatment. They say don't expect silver bullet (for curing MBC).
But I want to see them going out on a leg and putting up a X-prize for actually curing MBC. I want the silver bullet. HIV patients got silver bullets, diabetic patients got silver bullets, malaria folks got the silver bullets, some leukemia folks got the silver bullets. MBC and other cancer folks need to expect silver bullets and ask for the silver bullet (or the silver bullets) and not be distracted by any other shiny toys.
No more new mammograms, MRIs, PETs, and other half-baked detection/prevention mechanisms.
No more expensive drugs by extending MBC survival by 1 month, 3 month, etc.
No more adjuvant repackaging and remarketing of ok/great MBC drug that does not cure MBC and spend billions and 10 years to find out that this adjuvant strategy may not work.
No more quakery.
We have a real chance of getting the cure by 2020. But let's make sure of it.
I'm reading up on their progress report:
I like the fact that NBCC put a deadline date for BC. This is unlike other charities that just splashes pink year after year till the founders live to a cushy retirement, and generations of women get marched through the adjuvant BC revenue generation therapy and get decimated by the MBC.
http://www.breastcancerdeadline2020.org/about-the-deadline/progress-reports/2012-progress-report.html
They fund a project called artemis that tries to end breast cancer by preventing metastatic breast cancer(MBC), it's another way of saying they are going to end breast cancer by researching adjuvant BC treatment. They say don't expect silver bullet (for curing MBC).
But I want to see them going out on a leg and putting up a X-prize for actually curing MBC. I want the silver bullet. HIV patients got silver bullets, diabetic patients got silver bullets, malaria folks got the silver bullets, some leukemia folks got the silver bullets. MBC and other cancer folks need to expect silver bullets and ask for the silver bullet (or the silver bullets) and not be distracted by any other shiny toys.
No more new mammograms, MRIs, PETs, and other half-baked detection/prevention mechanisms.
No more expensive drugs by extending MBC survival by 1 month, 3 month, etc.
No more adjuvant repackaging and remarketing of ok/great MBC drug that does not cure MBC and spend billions and 10 years to find out that this adjuvant strategy may not work.
No more quakery.
We have a real chance of getting the cure by 2020. But let's make sure of it.
Wednesday, August 21, 2013
Miltefosine an anti-fungal/anti-protozoa drug may work on cutaneous BC
Old drug, response rate not that great (30%) not for too long either. but interesting.
xtandi is also being tested for androgen positive TNBC.
xtandi is also being tested for androgen positive TNBC.
Monday, August 19, 2013
Oncology Pipeline
Quoted below:
I'm also looking at GL-ONC1 and a few others.
http://www.onclive.com/publications/oncology-business-news/2013/june-2013/mining-the-pipeline-leading-investigational-products-and-areas-of-unmet-need/3
http://www.onclive.com/publications/oncology-live/2013/july-2013/immunotherapy-hits-new-peak-asco-data-stir-excitement-investment/3
Table 1. Pipeline Agents with the Greatest Potential Impact in Oncology
| Drug in Development | Manufacturer | Indications |
| Astuprotimut-r | GlaxoSmithKline | Melanoma, NSCLC |
| Ibrutinib | Pharmacyclics/ Johnson & Johnson | Chronic lymphocytic leukemia, mantle cell leukemia |
| Nivolumab | Bristol-Myers Squibb | Melanoma, NSCLC, renal cell carcinoma |
| Onartuzumab | Genentech/Roche | Gastric, NSCLC |
| Ramucirumab | Eli Lilly | Breast, colorectal, gastric, hepatoceullular carcinoma, NSCLC |
| Palbociclib | Pfizer | Breast |
| Rivantinib | ArQule/ Daiichi Sankyo | Hepatocellular carcinoma |
| Dabrafenib + Trametinib | GlaxoSmithKline | Melanoma |
Attributes that were scored included mechanistic innovation, strength of prior published data, target indication population size, and level of competition. For more in-depth information on Kantar Health’s scoring methodology, please e-mail info@kantarhealth.com.
I'm also looking at GL-ONC1 and a few others.
http://www.onclive.com/publications/oncology-business-news/2013/june-2013/mining-the-pipeline-leading-investigational-products-and-areas-of-unmet-need/3
Table. Ongoing Phase III Immunotherapy Clinical Trials
| Agent | Description | Tumor Type | Sponsor |
| AGS-003 | Autologous dendritic cell | RCC | Argos Therapeutics |
| BioVaxID (BV301) | Autologous immunoglobulin idiotype | Follicular lymphoma | Biovest International |
| BV-NSCLC-001 | Epithelial growth factor antigen | NSCLC | Bioven Europe |
| DCVax-L | Autologous dendritic cells | Glioblastoma multiforme | Northwest Biotherapeutics |
| GV1001 | Telomerase peptide | NSCLC | Kael-GemVax Co, Ltd |
| HyperAcute-Pancreas (algenpantucel-L) | Alpha-gal-modified cancer cells | Pancreatic | NewLink Genetics Corporation |
| IMA901 | Multipeptide | RCC | immatics Biotechnologies GmbH |
| Imprime PGG | β-glucan bound to neutrophils | Colorectal | Biothera |
| Lambrolizumab (MK-3475) | Anti-PD-1 monoclonal antibody | Melanoma | Merck |
| L-BLP25 (formerly Stimuvax) | MUC-1 peptide liposomal | NSCLC | Oncothyreon/Merck KgaA |
| Lucanix (belagenpumatucel-L) | Gene-modified TGF-β blocker | NSCLC | NovaRx Corporation |
| MAGE-A3 (astuprotimut) | Peptide-based | Melanoma; NSCLC | GlaxoSmithKline |
| Multikine (leukocyte interleukin) | Cytokine mixture | Oral cavity/soft palate | CEL-SCI Corporation |
| M-Vax | Autologous, hapten-modified | Melanoma | Avax Technologies |
| NeuVax (nelipepimut) | E75 peptide plus GM-CSF | Breast cancer | Galena Biopharma, Inc |
| Nivolumab (BMS-936558) | Anti-PD-1 monoclonal antibody | Melanoma; NSCLC; RCC | Bristol-Myers Squibb |
| POL-103A | Melanoma cell line antigens | Melanoma | Polynoma LLC |
| ProstAtak | Gene-mediated | Prostate | Advantagene, Inc |
| PROSTVAC | Poxviruses plus costimulatory molecules | Prostate | Bavarian Nordic |
| Rindopepimut (CDX-110) | EGFRv3-specific peptide conjugated to KLH | Glioblastoma | Celldex Therapeutics |
| Talimogene laherparepvec (T-VEC) | Genetically modified herpes oncolytic virus | Melanoma | Amgen |
| Vaxira (racotumomab) | Anti-idotypic monoclonal antibody | NSCLC | Recombio SL |
| Yervoya (ipilimumab) | Anti-CTLA-4 monoclonal antibody | Melanoma; NSCLC; prostate | Bristol-Myers Squibb |
Sources
Cancer Research Institute, ClinicalTrials.gov, company websites
- See more at: http://www.onclive.com/publications/oncology-live/2013/july-2013/immunotherapy-hits-new-peak-asco-data-stir-excitement-investment/3#sthash.Qgdo77vY.dpufCancer Research Institute, ClinicalTrials.gov, company websites
http://www.onclive.com/publications/oncology-live/2013/july-2013/immunotherapy-hits-new-peak-asco-data-stir-excitement-investment/3
Tuesday, August 13, 2013
TNBC may respond to blood cancer Multiple Myeloma Drug
Cancer cell has an interesting new paper, very early stages of course:
http://www.healthcanal.com/cancers/breast-cancer/41802-aggressive-triple-negative-breast-cancers-may-be-sensitive-to-drugs-that-clog-their-waste-disposal.html
Quote:
By selectively turning genes off throughout the genomes of triple-negative tumor cells in vitro, Lieberman's team found that these cells absolutely require active proteasomes in order to live. When turned off, the cells die.
These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade®), a proteasome inhibitor that revolutionized the care of patients with the blood cancer multiple myeloma.
http://www.healthcanal.com/cancers/breast-cancer/41802-aggressive-triple-negative-breast-cancers-may-be-sensitive-to-drugs-that-clog-their-waste-disposal.html
Quote:
By selectively turning genes off throughout the genomes of triple-negative tumor cells in vitro, Lieberman's team found that these cells absolutely require active proteasomes in order to live. When turned off, the cells die.
These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade®), a proteasome inhibitor that revolutionized the care of patients with the blood cancer multiple myeloma.
Friday, August 9, 2013
not exciting but interesting
http://www.sciencedaily.com/releases/2013/06/130605111527.htm
Lengthening drug response 30% sounds not too bad, except when you notice that you are still talking about a couple months more time, maybe. 15 years of MBC living is still the exception, not the rule by any form.
http://www.mountsinai.org/about-us/newsroom/press-releases/blocking-sugar-intake-may-reduce-cancer-risk-or-progression-in-obese-and-diabetic-people
Multitarget drug cocktail may be the way to go. But the number of clinical trials that needs to go through is staggering.
Quote: Armed with three new drug targets—glucose, the Ras/Src oncogenes, and Wingless/Wnt signaling—Dr. Cagan and his team identified compounds that can block the process.
They treated the flies with acarbose, a treatment for diabetes; a compound called AD81; and a drug called pyrvinium. Acarbose blocked sugar conversion to glucose; AD81 cut off Ras/Src and caused cell death; and pyrvinium inhibited Wingless/Wnt signaling. Taken together, this cocktail of drugs substantially reduced tumor size and progression.
“Our study shows that sugar activates oncogenes in the tumor, which then promote insulin sensitivity, meaning that the exorbitant glucose levels in the blood pour into the tumor, having nowhere else to go in the insulin-resistant body,” said Dr. Cagan. “We have identified a three-drug combination that stops this signaling activity and tumor growth in its tracks, without affecting normal cell function.”
Lengthening drug response 30% sounds not too bad, except when you notice that you are still talking about a couple months more time, maybe. 15 years of MBC living is still the exception, not the rule by any form.
http://www.mountsinai.org/about-us/newsroom/press-releases/blocking-sugar-intake-may-reduce-cancer-risk-or-progression-in-obese-and-diabetic-people
Multitarget drug cocktail may be the way to go. But the number of clinical trials that needs to go through is staggering.
Quote: Armed with three new drug targets—glucose, the Ras/Src oncogenes, and Wingless/Wnt signaling—Dr. Cagan and his team identified compounds that can block the process.
They treated the flies with acarbose, a treatment for diabetes; a compound called AD81; and a drug called pyrvinium. Acarbose blocked sugar conversion to glucose; AD81 cut off Ras/Src and caused cell death; and pyrvinium inhibited Wingless/Wnt signaling. Taken together, this cocktail of drugs substantially reduced tumor size and progression.
“Our study shows that sugar activates oncogenes in the tumor, which then promote insulin sensitivity, meaning that the exorbitant glucose levels in the blood pour into the tumor, having nowhere else to go in the insulin-resistant body,” said Dr. Cagan. “We have identified a three-drug combination that stops this signaling activity and tumor growth in its tracks, without affecting normal cell function.”
Subscribe to:
Posts (Atom)